Novo Nordisk A/S (FRA:NOV)

Market Cap	179.12B -49.2%
Revenue (ttm)	41.38B +6.4%
Net Income	13.72B +1.4%
EPS	3.08 +1.8%
Shares Out	n/a
PE Ratio	13.06
Forward PE	14.39
Dividend	1.56 (3.90%)
Ex-Dividend Date	Aug 15, 2025

Volume	22,016
Average Volume	32,681
Open	41.10
Previous Close	41.50
Day's Range	39.99 - 41.54
52-Week Range	35.96 - 90.42
Beta	n/a
RSI	37.98
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 69,150
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NOV

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK